Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach $51.9 Billion by 2030
The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$28.7 Billion in the year 2022, is projected to reach a revised size of US$51.9 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2022-2030. Stimulant, one of the segments analyzed in the report, is projected to record 7.2% CAGR and reach US$43 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Stimulant segment is readjusted to a revised 10.2% CAGR for the next 8-year period.The U.S. Market is Estimated at $8.4 Billion, While China is Forecast to Grow at 7.2% CAGR
The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$9 Billion by the year 2030 trailing a CAGR of 7.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 6.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.Select Competitors (Total 27 Featured) -
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Curemark, LLC
- Eli Lilly and Company
- Intellipharmaceutics International, Inc.
- Janssen Global Services, LLC
- Mallinckrodt PLC
- Mylan NV
- Neos Therapeutics, Inc.
- Neurovance, Inc.
- Noven Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire plc
- Supernus Pharmaceuticals, Inc.
- Tris Pharma, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alcobra Ltd.
- Amarantus Bioscience Holdings, Inc.
- Curemark, LLC
- Eli Lilly and Company
- Intellipharmaceutics International, Inc.
- Janssen Global Services, LLC
- Mallinckrodt PLC
- Mylan NV
- Neos Therapeutics, Inc.
- Neurovance, Inc.
- Noven Pharmaceuticals, Inc.
- Pfizer Inc.
- Shire plc
- Supernus Pharmaceuticals, Inc.
- Tris Pharma, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 186 |
Published | May 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 28.7 Billion |
Forecasted Market Value ( USD | $ 51.9 Billion |
Compound Annual Growth Rate | 7.7% |
Regions Covered | Global |